Related references
Note: Only part of the references are listed.Safety and immunogenicity of the α-synuclein active immunotherapeutic PDO1A in patients with Parkinson's disease: a randomised, single-blinded, phase 1 trial
Dieter Volc et al.
LANCET NEUROLOGY (2020)
Phase II Dose Selection for Alpha Synuclein-Targeting Antibody Cinpanemab (BIIB054) Based on Target Protein Binding Levels in the Brain
Mita Kuchimanchi et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2020)
α-Synuclein misfolding and aggregation: Implications in Parkinson's disease pathogenesis
Surabhi Mehra et al.
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS (2019)
Development of an aggregate-selective, human-derived α-synuclein antibody BIIB054 that ameliorates disease phenotypes in Parkinson's disease models
Andreas Weihofen et al.
NEUROBIOLOGY OF DISEASE (2019)
State transitions in the substantia nigra reticulata predict the onset of motor deficits in models of progressive dopamine depletion in mice
Amanda M. Willard et al.
ELIFE (2019)
Alpha-Synuclein Pathology and the Role of the Microbiota in Parkinson's Disease
Emily Fitzgerald et al.
FRONTIERS IN NEUROSCIENCE (2019)
Randomized phase I clinical trial of anti-α-synuclein antibody BIIB054
Miroslaw Brys et al.
MOVEMENT DISORDERS (2019)
Dementia with Lewy bodies: an update and outlook
Tiago Fleming Outeiro et al.
MOLECULAR NEURODEGENERATION (2019)
Preclinical development of a high affinity α-synuclein antibody, MEDI1341, that can enter the brain, sequester extracellular α-synuclein and attenuate α-synuclein spreading in vivo
Darren J. Schofield et al.
NEUROBIOLOGY OF DISEASE (2019)
Autoimmunity in Parkinson's Disease: The Role of α-Synuclein-Specific T Cells
Francesca Garretti et al.
FRONTIERS IN IMMUNOLOGY (2019)
Emerging Immunotherapies for Parkinson Disease
Samis M. A. Zella et al.
NEUROLOGY AND THERAPY (2019)
Dopamine and Levodopa Prodrugs for the Treatment of Parkinson's Disease
Fatma Haddad et al.
MOLECULES (2018)
Extracellular α-synuclein levels are regulated by neuronal activity
Kaoru Yamada et al.
MOLECULAR NEURODEGENERATION (2018)
Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-β
Joseph W. Arndt et al.
SCIENTIFIC REPORTS (2018)
Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti-a-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease A Randomized Clinical Trial
Joseph Jankovic et al.
JAMA NEUROLOGY (2018)
Mechanisms of α-Synuclein Induced Synaptopathy in Parkinson's Disease
Jessika C. Bridi et al.
FRONTIERS IN NEUROSCIENCE (2018)
First-in-human assessment of PRX002, an anti--synuclein monoclonal antibody, in healthy volunteers
Dale B. Schenk et al.
MOVEMENT DISORDERS (2017)
Epidemiology of Parkinson's disease
Ole-Bjorn Tysnes et al.
JOURNAL OF NEURAL TRANSMISSION (2017)
Structural basis of membrane disruption and cellular toxicity by α-synuclein oligomers
Giuliana Fusco et al.
SCIENCE (2017)
Antibodies against the C-terminus of alpha-synuclein modulate its fibrillation
Cagla Sahin et al.
BIOPHYSICAL CHEMISTRY (2017)
Current approaches to the treatment of Parkinson's Disease
J. Michael Ellis et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2017)
Monoamine Oxidase B Inhibitors in Parkinson's Disease
Livia Dezsi et al.
CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS (2017)
Synaptic failure and α-synuclein
Laura Calo et al.
MOVEMENT DISORDERS (2016)
The antibody aducanumab reduces Aβ plaques in Alzheimer's disease
Jeff Sevigny et al.
NATURE (2016)
Alpha-Synuclein in Parkinson's Disease: From Pathogenetic Dysfunction to Potential Clinical Application
Lingjia Xu et al.
PARKINSONS DISEASE (2016)
Exposure to bacterial endotoxin generates a distinct strain of α-synuclein fibril
Changyoun Kim et al.
SCIENTIFIC REPORTS (2016)
Mechanism of Anti-alpha-Synuclein Immunotherapy
Jun Sung Lee et al.
JOURNAL OF MOVEMENT DISORDERS (2016)
Toxic species in amyloid disorders: Oligomers or mature fibrils
Meenakshi Verma et al.
ANNALS OF INDIAN ACADEMY OF NEUROLOGY (2015)
Neuronal Aggregates: Formation, Clearance, and Spreading
Junghyun Lim et al.
DEVELOPMENTAL CELL (2015)
Catechol-O-Methyltransferase Inhibitors in Parkinson's Disease
Thomas Mueller
DRUGS (2015)
Active immunization against alpha-synuclein ameliorates the degenerative pathology and prevents demyelination in a model of multiple system atrophy
Markus Mandler et al.
MOLECULAR NEURODEGENERATION (2015)
α-Synuclein strains cause distinct synucleinopathies after local and systemic administration
W. Peelaerts et al.
NATURE (2015)
Structural basis of antizyme-mediated regulation of polyamine homeostasis
Hsiang-Yi Wu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Immunotherapy in Parkinson's Disease: Micromanaging Alpha-Synuclein Aggregation
Sonia George et al.
JOURNAL OF PARKINSONS DISEASE (2015)
Next-generation active immunization approach for synucleinopathies: implications for Parkinson's disease clinical trials
Markus Mandler et al.
ACTA NEUROPATHOLOGICA (2014)
UV-induced selective oxidation of Met5 to Met-sulfoxide leads to the formation of neurotoxic fibril-incompetent α-synuclein oligomers
Phelippe Carmo-Goncalves et al.
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2014)
Reducing C-Terminal-Truncated Alpha-Synuclein by Immunotherapy Attenuates Neurodegeneration and Propagation in Parkinson's Disease-Like Models
Dora Games et al.
JOURNAL OF NEUROSCIENCE (2014)
Lysine residues at the first and second KTKEGV repeats mediate α-Synuclein binding to membrane phospholipids
Yonaton Zarbiv et al.
NEUROBIOLOGY OF DISEASE (2014)
Alpha-Synuclein Function and Dysfunction on Cellular Membranes
David Snead et al.
Experimental Neurobiology (2014)
The many faces of alpha-synuclein: from structure and toxicity to therapeutic target
Hilal A. Lashuel et al.
NATURE REVIEWS NEUROSCIENCE (2013)
Antibody-Aided Clearance of Extracellular α-Synuclein Prevents Cell-to-Cell Aggregate Transmission
Eun-Jin Bae et al.
JOURNAL OF NEUROSCIENCE (2012)
Exosomal cell-to-cell transmission of alpha synuclein oligomers
Karin M. Danzer et al.
MOLECULAR NEURODEGENERATION (2012)
Pathological α-Synuclein Transmission Initiates Parkinson-like Neurodegeneration in Nontransgenic Mice
Kelvin C. Luk et al.
SCIENCE (2012)
Mitochondrial Biology and Parkinson's Disease
Celine Perier et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2012)
Incidental Lewy body disease: Do some cases represent a preclinical stage of dementia with Lewy bodies?
Roberta Frigerio et al.
NEUROBIOLOGY OF AGING (2011)
Passive Immunization Reduces Behavioral and Neuropathological Deficits in an Alpha-Synuclein Transgenic Model of Lewy Body Disease
Eliezer Masliah et al.
PLOS ONE (2011)
Antibodies against Alpha-Synuclein Reduce Oligomerization in Living Cells
Thomas Nasstrom et al.
PLOS ONE (2011)
In vivo demonstration that α-synuclein oligomers are toxic
Beate Winner et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
A Therapeutic Antibody Targeting BACE1 Inhibits Amyloid-β Production in Vivo
Jasvinder K. Atwal et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
MPTP Mouse Models of Parkinson's Disease: An Update
Gloria E. Meredith et al.
JOURNAL OF PARKINSONS DISEASE (2011)
Lewy body pathology in fetal grafts
Yaping Chu et al.
YEAR IN NEUROLOGY 2 (2010)
Direct Transfer of α-Synuclein from Neuron to Astroglia Causes Inflammatory Responses in Synucleinopathies
He-Jin Lee et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Cellular strategies for controlling protein aggregation
Jens Tyedmers et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2010)
Molecular mechanisms of excitotoxicity and their relevance to pathogenesis of neurodegenerative diseases
Xiao-xia Dong et al.
ACTA PHARMACOLOGICA SINICA (2009)
A critical evaluation of current staging of α-synuclein pathology in Lewy body disorders
Kurt A. Jellinger
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2009)
Formation of dopamine-mediated α-synuclein-soluble oligomers requires methionine oxidation
Su Ling Leong et al.
FREE RADICAL BIOLOGY AND MEDICINE (2009)
Alpha-synuclein overexpression and aggregation exacerbates impairment of mitochondrial functions by augmenting oxidative stress in human neuroblastoma cells
Mordhwaj S. Parihar et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2009)
Mitochondrial import and accumulation of α-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain
Latha Devi et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Mechanism of alpha-synuclein oligomerization and membrane interaction: theoretical approach to unstructured proteins studies
Igor F. Tsigelny et al.
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE (2008)
Modulation of α-Synuclein Expression in Transgenic Animals for Modelling Synucleinopathies - is the Juice Worth the Squeeze?
Vladimir L. Buchman et al.
NEUROTOXICITY RESEARCH (2008)
Mechanisms of Hybrid Oligomer Formation in the Pathogenesis of Combined Alzheimer's and Parkinson's Diseases
Igor F. Tsigelny et al.
PLOS ONE (2008)
The Lewy body in Parkinson's disease:: Molecules implicated in the formation and degradation of α-synuclein aggregates
Koichi Wakabayashi et al.
NEUROPATHOLOGY (2007)
Different species of α-synuclein oligomers induce calcium influx and seeding
Karin M. Danzer et al.
JOURNAL OF NEUROSCIENCE (2007)
Internalized antibodies to the Aβ domain of APP reduce neuronal Aβ and protect against synaptic alterations
Davide Tampellini et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Catechol-O-methyltransferase and its inhibitors in Parkinson's disease
Maria Joao Bonifacio et al.
CNS DRUG REVIEWS (2007)
Parkinson's disease: lesions in dorsal horn layer I, involvement of parasympathetic and sympathetic pre- and postganglionic neurons
Heiko Braak et al.
ACTA NEUROPATHOLOGICA (2007)
Parkinson's disease α-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death
LJ Martin et al.
JOURNAL OF NEUROSCIENCE (2006)
Effects of α-synuclein immunization in a mouse model of Parkinson's disease
E Masliah et al.
NEURON (2005)
Profound cardiac sympathetic denervation occurs in Parkinson disease
T Amino et al.
BRAIN PATHOLOGY (2005)
Hsp70 reduces α-synuclein aggregation and toxicity
J Klucken et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Alpha-synuclein degradation by serine protease neurosin: implication for pathogenesis of synucleinopathies
A Iwata et al.
HUMAN MOLECULAR GENETICS (2003)
α-synuclein is degraded by both autophagy and the proteasome
JL Webb et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Limitations of current Parkinson's disease therapy
O Rascol et al.
ANNALS OF NEUROLOGY (2003)
Oxidative stress in Parkinson's disease
P Jenner
ANNALS OF NEUROLOGY (2003)
Neuronal α-synucleinopathy with severe movement disorder in mice expressing A53T human α-synuclein
BI Giasson et al.
NEURON (2002)
14-3-3 proteins in Lewy bodies in Parkinson disease and diffuse Lewy body disease brains
Y Kawamoto et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2002)
What does it mean to be natively unfolded?
VN Uversky
EUROPEAN JOURNAL OF BIOCHEMISTRY (2002)
Novel mitochondrial DNA mutations in Parkinson's disease
G Richter et al.
JOURNAL OF NEURAL TRANSMISSION (2002)
Selective insolubility of α-Synuclein in human Lewy body diseases is recapitulated in a transgenic mouse model
PJ Kahle et al.
AMERICAN JOURNAL OF PATHOLOGY (2001)
Share Paper
